FDA Greenlights First Drug to Attack Pancreatic Cancer's Genetic Engine

The FDA approved daraxonrasib, marketed as Rasonque, a first-in-class drug that tackles the mutated RAS proteins driving 90% of pancreatic tumors—finally cracking a biological target long deemed "undruggable."

Vital Signs

Key statistics from the pivotal trial reveal a stark contrast in survival outcomes:

• 13.2 months — median survival for patients on Rasonque
• 6.7 months — median survival with standard chemotherapy
• 67,000 — estimated new pancreatic...